Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

On Tuesday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $98.58 which represents a decrease of $-2.15 or -2.13% from the prior close of $100.73. The stock opened at $100.76 and touched ...

In my view, based on what's coming up for Merck, it's likely that investors with some patience will find the stock to be more ...

Investing.com -- Shares of Merck KGaA (ETR: MRCG) fell over 4% on Thursday following a mixed reception to its third-quarter ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...

Shares of Merck & Co. Inc. MRK inched 0.44% higher to $101.17 Thursday, on what proved to be an all-around mixed trading ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

The S&P 500 rallied in the wake of last week's election results, climbing 3.8% since Nov. 5 at Wednesday's prices. But not ...

In my view, based on what's coming up for Merck, it's likely that investors with some patience will find the stock to be more appealing. Understanding the investment thesis for Merck requires ...